Exelixis, Inc.

Schering Aktiengesellschaft

Berlex Laboratories, Inc.

Smith International, Inc.

Weatherford Technology Holdings, LLC

Weatherford/lamb, Inc.

Symphony Evolution, Inc.

Bristol-myers Squibb Compnay

Exelixis Patent Company LLC

Bayer Schering Pharma Ag

Wei Xu

Michael M Morrissey

Brad Owen Buckman

Howard P Ng

Guo Ping Wei

Gary Bruce Phillips

John M Nuss

David D Davey

Yong Wang

Lynne Canne Bannen

Imadul Islam

William J Guilford

Shung C Wu

Charles H Dewey

Moon Jung Kim

Albert C Odell, Ii

Raju Mohan

Vasu Jammalamadaka

Morrison B Mac

Erick Wang Co

Donna Tra Le

Sean D Monahan

Zuchun Zhao

Meina Liang

John G Bauman

Kenneth Jay Shaw

Richard Horuk

Joseph E Hesselgesser

Amy Lew Tsuhako

Karen B May

Ameen F Ghannam

Shendong Yuan

S David Brown

Judi Bryant

John Edward Campbell

Minna Bui

Richard George Khoury

Jason Jevious Parks

Shumeye Mamo

Patrick C Kearney

Tuong Thanh Le

Elena S Koltun

James William Leahy

Eric Michael Twardowski

Thomas M Redlinger

Larry Wayne Mann

Ping Huang

Jose A Trevino

Sunghoon Ma

Lisa Esther Dalrymple

Diva Sze-Ming Chan

Simon John Harrall

Kin Tso

David J Brunnert

Frederick Thomas Tilton

Timothy Patrick Forsyth

Naing N Aay

Joerg Bussenius

Dana T Aftab

Jeff Z Chen

Michael P Prisbylla

Grace Mann

Tai Phat Huynh

Craig Stacy Takeuchi

Michael J Moody

Andrew Antoine

Tommy Laird

Sriram Naganathan

Richard Lee Giroux

Matthew A Williams

T G Murali Dhar

Richard Martin

Mark J Murray

Neel Kumar Anand

Thurman B Carter

Tsze Tsang

Tie-Lin Wang

Kenneth D Rice

Jack Maung

Charles M Blazey

Atwood Kim Cheung

Brett Bradley Busch

Simona Costanzo

Brian Cruickshank

Xiao-Hui Gu

Larisa Dubenko

Steven T Sakata

Brant Clayton Boren

Owen Joseph Bowles

Cristiana A Zaharia

David J Donnelly

Brian Hugh Ridgway

Jeffry Kimo Curtis

Edwin J Schweiger

Linh Nguyen

Sergey Epshteyn

William C Stevens, Jr

Joan C Sangalang

Xian Shi

Steven Charles Defina

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.

Pyridone compounds and methods of use

Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine receptors are disclosed herein. Also disclosed herein are pharmaceutical compositions and methods of administration of heterocyclic antagonists of adenosine receptors and processes for producing heterocyclic antagonists of adenosine receptors.

Heterocyclic adenosine receptor antagonists

Disclosed herein are compounds of Formula (I′). Compounds of Formula (I′) inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

Compounds for the treatment of kinase-dependent disorders

Disclosed herein are compounds of Formula (I'). Compounds of Formula (I&#x2032;) inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

Disclosed herein are compounds of Formula I'. Compounds of Formula I&#x2032; inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. 

Disclosed herein are compounds of formula I. Compounds of formula I inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. 

A tool for use in a wellbore includes a tubular body having a bore therethrough, an opening through a wall thereof, and a connector at each longitudinal end thereof; and an arm. The arm is pivotally connected to a first piston and rotationally coupled to the body, is disposed in the opening in a retracted position, and is movable to an extended position where an outer surface of the arm extends outward past an outer surface of the body. The first piston is disposed in the body bore, has a bore therethrough, and is operable to move the arm from the retracted position to the extended position in response to fluid pressure in the piston bore exceeding fluid pressure in the opening. The tool further includes a lock operable to retain the first piston in the retracted position; and a second piston operably coupled to the lock.

Extendable cutting tools for use in a wellbore

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

C-met modulators and methods of use

The present invention relates to a method of preparing Cabozantinib (Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylo]amide(4-fluoro-phenyl)amide) andF labeled Cabozantinib.

Method of preparing fluorine-18 labeled Cabozantinib and its analogs

A controller for operating a downhole tool includes a tubular body; a seat disposed in the body for receiving first and second pump-down plugs, at least a portion of one of the seat and the plugs being radially displaceable to pass through or allow passage of the other at a first threshold pressure differential; a catcher located below the seat for receiving the plugs after passing through the seat; a toggle linked to the seat to alternate between a locked position and an unlocked position in response to seating of the plugs; and a control mandrel for engaging a piston of the downhole tool and linked to the toggle: to be longitudinally movable between a first position and a second position when the toggle is unlocked, and to be prevented from movement from the first position to the second position when the toggle is locked.

Controller for downhole tool

The invention relates to metabolites of cabozantinib (I) as well as uses thereof. 

Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.

Dosing of cabozantinib formulations

Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R, R, R, R, R, R, R, x, y, L, G, Z, the bond denoted by 'q', the ring system denoted by 'A' and the ring system denoted by &#x201c;B&#x201d; are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders. 

ROR&#x3b3; modulators

A method of drilling a wellbore includes running a drilling assembly into the wellbore through a casing string, the drilling assembly having a tubular string, a stabilizer, and a drill bit; applying a force to an arm of the stabilizer, thereby causing the arm to retract; and removing the stabilizer and the drill bit from the wellbore.

Extendable and retractable stabilizer

Growing community of inventors

Danville, CA, United States of America

Wei Xu